2. Search Result
Search Result
Results for "

Brigatinib

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

2

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12857
    Brigatinib
    25+ Cited Publications

    AP-26113

    		 Anaplastic lymphoma kinase (ALK) Cancer
    Brigatinib (AP-26113) is a highly potent, selective and orally active ALK inhibitor, with an IC50 of 0.6 nM. Brigatinib can be used for research of NSCLC .
    Brigatinib
  • HY-13464
    ALK-IN-1

    Brigatinib analog

    		 Anaplastic lymphoma kinase (ALK) EGFR Cancer
    ALK-IN-1 is an orally active, blood-brain barrier-permeable ALK and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer .
    ALK-IN-1
  • HY-159147
    SIA​​IS039

    		PROTACs ROS Kinase Apoptosis Cancer
    SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC50s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) .
    SIA​​IS039
  • HY-150910
    Brigatinib C

    		PROTAC Linkers Cancer
    Brigatinib C is a linker, as a part of PROTAC Linker to target HJM-561 (HY-156698).
    Brigatinib C
  • HY-147219A
    SIAIS164018 hydrochloride

    		PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis Cancer
    SIAIS164018 hydrochloride is a PROTAC-based ALK and EGFR degrader, with IC50 value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 hydrochloride strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 hydrochloride exhibits better property than Brigatinib (HY-12857) .
    SIAIS164018 hydrochloride
  • HY-150908
    Brigatinib A

    		Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK) Cancer
    Brigatinib A is an GID4 ligand. Brigatinib A can be used for synthesizing PROTAC BCR-ABL Degrader-2 (HY-174368) .
    Brigatinib A
  • HY-147219
    SIAIS164018

    		PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis Cancer
    SIAIS164018 is a PROTAC-based ALK and EGFR degrader, with IC50 value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 exhibits better property than Brigatinib (HY-12857) .
    SIAIS164018
  • HY-12857S
    Brigatinib-13C6

    AP-26113-13C6

    		 Isotope-Labeled Compounds Anaplastic lymphoma kinase (ALK) Cancer
    Brigatinib- 13C6 is the 13C-labeled Brigatinib. Brigatinib (AP-26113) is a highly potent and selective ALK inhibitor, with an IC50 of 0.6 nM .
    Brigatinib-13C6
  • HY-12857R
    Brigatinib (Standard)

    AP-26113 (Standard)

    		 Anaplastic lymphoma kinase (ALK) Reference Standards Cancer
    Brigatinib (Standard) is the analytical standard of Brigatinib. This product is intended for research and analytical applications. Brigatinib (AP-26113) is a highly potent, selective and orally active ALK inhibitor, with an IC50 of 0.6 nM. Brigatinib can be used for research of NSCLC .
    Brigatinib (Standard)
  • HY-12857S2
    Brigatinib-d11

    AP-26113-d11

    		 Isotope-Labeled Compounds Anaplastic lymphoma kinase (ALK) Cancer
    Brigatinib-d11 (AP-26113-d11) is deuterium labeled Brigatinib. Brigatinib (AP-26113) is a highly potent, selective and orally active ALK inhibitor, with an IC50 of 0.6 nM. Brigatinib can be used for research of NSCLC .
    Brigatinib-d11
  • HY-13464R
    ALK-IN-1 (Standard)

    Brigatinib analog (Standard)

    		 Reference Standards Anaplastic lymphoma kinase (ALK) EGFR Cancer
    ALK-IN-1 (Standard) is the analytical standard of ALK-IN-1 (Brigatinib analog) (HY-13464). This product is intended for research and analytical applications. ALK-IN-1 is an ALK and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer .
    ALK-IN-1 (Standard)
  • HY-146022
    SIAIS117

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    SIAIS117 is a potent Brigatinib-PROTAC degrader. SIAIS117 is a ALK PROTAC based on Brigatinib and VHL-1 conjunction. SIAIS117 can degrade ALK G1202R point mutation effectively. SIAIS117 blocks the growth of SR and H2228 cancer cell lines. SIAIS117 has the potentially anti-proliferation ability of small cell lung cancer .
    SIAIS117
  • HY-143445
    EGFR-IN-48

    		EGFR Cancer
    EGFR-IN-48 is a potent and orally active EGFR inhibitor with IC50s of 0.193 nM, 0.251 nM, 10.4 nM for EGFR d19/TM/CS, EGFR LR/TM/CS, EGFR WT, respectively. EGFR-IN-48 inhibits the proliferation of BaF3 EGFR del19/T790M/C797S and PC-9 EGFR del19/T790M/C797S cells with IC50s of 1.526, 66.7 nM, respectively .
    EGFR-IN-48
  • HY-182087
    ALK degrader 3

    		HyT Anaplastic lymphoma kinase (ALK) Cancer
    ALK degrader 3 is a ALK HyT degrader with an IC50 of 1.2 nM. ALK degrader 3 inhibits ALK kinase activity, increases the solvent-accessible surface area of hydrophobic residues near the ALK binding pocket, promotes ALK to form a partially unfolded conformation, and drives ALK degradation via the proteasomal pathway. ALK degrader 3 inhibits the proliferation of tumor cells. ALK degrader 3 can be used for the research of non-small cell lung cancer. (ALK ligand: Brigatinib (HY-12857); hydrophobic tag: Tetraasterane (HY-W1139353)) .
    ALK degrader 3
  • HY-182057
    ALK degrader 4

    		HyT Anaplastic lymphoma kinase (ALK) Cancer
    ALK degrader 4 is a ALK HyT degrader with an IC50 of 0.74 nM. ALK degrader 4 inhibits ALK kinase activity, increases the solvent-accessible surface area of hydrophobic residues near the ALK binding pocket, promotes ALK to form a partially unfolded conformation, and induces proteasomal degradation of ALK. ALK degrader 4 inhibits cancer cell proliferation. ALK degrader 4 can be used in research related to non-small cell lung cancer (ALK ligand: Brigatinib (HY-12857); hydrophobic tag: Norbornene (HY-W013021)) .
    ALK degrader 4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: